AZ China Growth Pops Again But Clouds Loom
Executive Summary
Lying underneath AstraZeneca’s stellar quarter were the growth engines of emerging markets and China, where novel drugs, especially in oncology, delivered. But mounting pricing pressures and a massive new centralized bidding process are clouds on the horizon.
You may also be interested in...
Asia Deal Watch: ASLAN, Bukwang Establish Immuno-Oncology JV In Singapore
The JV to be called JAGUAHR Therapeutics will focus on the AhR pathway. Simcere acquires Chinese rights to JW’s gout candidate.
Tagrisso Climbs Close To Top Of AstraZeneca Sales Tree
The drug major has presented a set of financials that have comfortably surpassed analyst forecasts and show that its new oncology therapies now make up around 30% of group sales and are growing strongly.
First Approval For AZ's Roxadustat With China Green Light
China is the first country to give the green light to roxadustat, AstraZeneca and FibroGen's first-in-class oral inhibitor of HIF-PHI, which could become standard of care to treat anemia in chronic kidney disease patients.